A Standalone PD-1 Chimeric Switch Receptor T-Cell Platform Expands the Therapeutic Window of PD-L1 Targeting in Solid Tumors

Two lead PD-1 chimeric switch receptor T-cell candidates retain potent PD-L1 tumor killing while markedly reducing cytotoxicity toward primary human normal cells.

• Why it matters: PD-L1 targeting is constrained by physiological PD-L1 expression in normal tissues, creating on-target/off-tumor toxicity risk that limits the therapeutic window for cellular therapies.
• What they did: The team engineered PD-1 CSR T cells using iterative receptor design, selecting candidates by parallel measures of antitumor activity and normal-cell reactivity, then tested them in 3D organoids and orthotopic or patient-derived glioblastoma models.
• The result: The candidates eliminated PD-L1-positive immunosuppressive myeloid cells and suppressed tumor growth while prolonging survival after systemic or intracranial dosing, supporting a standalone platform that improves tumor-normal discrimination.

AI summary of the abstract · may contain errors · not medical advice · read the paper.